Sanjay Logani, MD
Retina Specialist · Reseda, CANPI 1124131958
Payments from drug & device makers
Across 266 payments — averaging $34.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$2K
- Novartis$853
- Regeneron Healthcare Solutions, Inc.$789
- Sun Pharmaceutical Industries Inc.$701
- Alcon$649
- AbbVie$535
- plus $4K from 22 others
What the payments were for
- Food & beverage$7,34180%
- Gifts$390%
- Entertainment$190%
- Other$1,81720%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 2 | $1,817 |
| Novartis | 51 | $853 |
| Regeneron Healthcare Solutions, Inc. | 14 | $789 |
| Sun Pharmaceutical Industries Inc. | 22 | $701 |
| Alcon | 15 | $649 |
| AbbVie(2 entities) | 26 | $535 |
| Glaukos Corporation | 10 | $524 |
| Amgen(2 entities) | 29 | $479 |
| Bausch & Lomb Americas Inc. | 20 | $430 |
| Johnson & Johnson Surgical Vision, Inc. | 10 | $410 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $316 |
| Dompe US, Inc. | 6 | $244 |
| Harrow Eye, LLC | 12 | $223 |
| Oyster Point Pharma, Inc. | 10 | $210 |
| Sight Sciences, Inc. | 4 | $149 |
| Alimera Sciences, Inc. | 7 | $136 |
| Eyepoint US, Inc. | 1 | $125 |
| Biotissue Holdings Inc. | 6 | $125 |
| Genentech USA, Inc. | 3 | $103 |
| Tarsus Pharmaceuticals, Inc. | 3 | $101 |
| Quidel Corporation | 1 | $92 |
| Shire North American Group Inc | 2 | $47 |
| Beaver-visitec International, Inc. | 1 | $43 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Eyevance Pharmaceuticals LLC | 1 | $27 |
| Optos, Inc. | 1 | $19 |
| Kala Pharmaceuticals, Inc. | 1 | $18 |
| Vyera Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,215 in reported general payments places this provider in the 60th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MieboPerfluorohexyloctane/Pf | 131 | $140,511 |
| XiidraLifitegrast | 192 | $135,372 |
| CequaCyclosporine | 215 | $131,561 |
| XdemvyLotilaner | 60 | $109,741 |
| Cyclosporine | 226 | $67,739 |
| RestasisCyclosporine | 91 | $58,031 |
| Azelastine Hcl | 611 | $17,256 |
| TyrvayaVarenicline Tartrate | 26 | $17,199 |
| LumiganBimatoprost | 46 | $16,449 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $4,576 |
| CombiganBrimonidine Tartrate/Timolol | 15 | $4,456 |
| Prednisolone Acetate | 125 | $4,438 |
| TobradexTobramycin/Dexamethasone | 17 | $4,377 |
| Ofloxacin | 347 | $3,428 |
| Brimonidine Tartrate | 53 | $2,634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $430 | $275,883323 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $701 | $131,561215 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $101 | $109,74160 claims |
| AbbVieRestasis, Lumigan, Combigan | $535 | $78,936152 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $210 | $17,19926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 187 retina specialist providers in California.
Other retina specialist in Reseda
- Dante PieramiciSanta Barbara$15.1M
- Margaret ChangSacramento$13.2M
- Hani Salehi-HadHuntington Beach$12.2M
- Payam AminiPasadena$9.9M
- Joel PearlmanSacramento$8.3M
- Dilsher DhootSanta Barbara$8.2M
- Ashkan PirouzFullerton$6.9M
- Roger GoldbergWalnut Creek$5M
- Sean AdreanFullerton$2.9M
- Nathan SteinleSanta Barbara$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.